Clearstead Advisors LLC Purchases 5,458 Shares of Medtronic PLC $MDT

Clearstead Advisors LLC lifted its position in shares of Medtronic PLC (NYSE:MDT) by 14.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,117 shares of the medical technology company’s stock after acquiring an additional 5,458 shares during the quarter. Clearstead Advisors LLC’s holdings in Medtronic were worth $4,202,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Delos Wealth Advisors LLC acquired a new position in Medtronic during the 2nd quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic during the third quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new position in Medtronic in the third quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. bought a new position in Medtronic in the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in Medtronic during the 3rd quarter worth $34,000. Institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on MDT. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Morgan Stanley boosted their target price on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Daiwa Securities Group lifted their price objective on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Finally, Mizuho raised shares of Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $110.84.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Medtronic Stock Up 1.7%

MDT stock opened at $98.54 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market capitalization of $126.33 billion, a P/E ratio of 27.45, a P/E/G ratio of 2.43 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The business has a 50-day moving average of $99.03 and a 200-day moving average of $96.80.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s payout ratio is currently 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).